Jubilant Life gets US regulator approval for anti-inflammatory drug

Jubilant Life Sciences has a total of 84 ANDAs for oral solids filed in the US

Indomethacin capsules are used in treatment of moderate to severe inflammation
Press Trust of India New Delhi
Last Updated : Aug 28 2017 | 3:57 PM IST
Jubilant Life Sciences Ltd today said it has received the final approval for its generic version of non-steroidal anti-inflammatory drug, Indocin, from the US health regulator.

The approval for Indomethacin capsules, generic equivalent of Indocin of Iroko, is for multiple strengths of 25 mg and 50 mg, the company said in a BSE filing.

Indomethacin capsules are used in treatment of moderate to severe inflammation and reduce pain.

Also Read

"This is the seventh approval that we have received from the USFDA during the current financial year," the company said.

Jubilant Life Sciences has a total of 84 ANDAs for oral solids filed in the US, of which 53 had been approved as on June 30, 2017, it said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 28 2017 | 3:57 PM IST

Next Story